Investors are ignoring the FDA's internal chaos, focusing instead on fundamentals that drive biotech valuations. After commissioner Marty Makary quit and senior leaders were swept out, the agency appears leaderless, yet market participants have demoted political risk below interest rates, earnings and clinical data. The Make America Healthy Again movement, championed by Robert F. Kennedy Jr. at HHS, still fuels public skepticism, but its impact on pricing and deal‑making is waning.

A fresh shake‑up hit the agency on Friday when Tracy Beth Høeg, head of the drug division and known Covid‑vaccine skeptic, announced her departure, followed by a replacement in the vaccine and biologics unit. Those exits signal a continuing purge of scientifically oriented staff, but investors are more concerned with who stays. Acting FDA chief Kyle Diamantas, a former Abbott Laboratories lawyer, is viewed as a predictable figure, offering the market a steadier regulatory outlook.

With the FDA's leadership revolving and the MAHA agenda losing traction among Wall Street, biotech companies can pursue pipelines and M&A with less political headwinds. The shift reorders risk hierarchies, placing clinical trial results and cash flow ahead of regulatory uncertainty. As a result, capital is flowing to drug developers based on their science and balance sheets rather than the agency's internal strife.